One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to SCENESSE in España. Product-specific FDA and EU medicine records.

Current source route

SCENESSE in España

Direct answer / España

Can you buy SCENESSE in España?

Product-specific FDA and EU medicine records

SCENESSE is a product-specific afamelanotide 16 mg implant authorized in the United States and European Union for narrowly defined erythropoietic protoporphyria uses. Those authorizations do not transfer to seller-labelled Melanotan I research vials, compounded products, other presentations, indications, online sellers, or supply routes, and they do not establish local availability in every country.

  1. 01
    Resolve the nameFDA-approved medicine
  2. 02
    Check EspañaFDA-approved medicine
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordProduct-specific FDA and EU medicine records

What SCENESSE resolves to

SCENESSE is a product-specific afamelanotide 16 mg implant authorized in the United States and European Union for narrowly defined erythropoietic protoporphyria uses. Those authorizations do not transfer to seller-labelled Melanotan I research vials, compounded products, other presentations, indications, online sellers, or supply routes, and they do not establish local availability in every country.

Evidence lane
FDA-approved medicine
Current record
NDA 210797 · FDA-approved prescription drug
Checked
July 17, 2026
afamelanotideScenesseCUV1647NDA 210797alpha-MSH analog
Destination recordMercado de medicamentos regulado

What España still has to prove

Una guía para España que separa el estado oficial del medicamento, la farmacia autorizada para venta a distancia y los materiales anunciados solo para investigación antes de comparar ofertas.

Comparison mode
EUR / CIMA, Distafarma y autorización
Price coverage
Sin vendedores clasificados
Guide updated
18 de julio de 2026
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail